Go BACK

OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 521 - 530 of 692 studies

Cancer and neoplasms

A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 with FOLFOX plus Cetuximab versus FOLFOX with or without Bevacizumab as First-line Treatment of Participants with KRAS G12C Mutant, Metastatic Colorectal Cancer

Cancer and neoplasms

A Phase II/III, multisite, randomized master protocol for a global trial of BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer

Establishment of a research register for patients and families of inherited cardiac condition/cardiomyopathy services (GenetICC)

Cancer and neoplasms

Safety, Tolerability, Pharmacokinetics, and Antitumour Activity of WEF-001 in participants with KRAS-Mutant Advanced Solid Tumours (WEF-001-01)

Neurological

A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart Versus Intravenous Immunoglobulin (IVIg) in Adults With Multifocal Motor Neuropathy (EMPASSION)

A Two-Year Double-masked, Randomized, Sham-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene (LUNA)

Eye

A Phase 1/2, First-in-Human, Open-label, Assessor-Masked, Randomized, Controlled, Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects with Stargardt Disease (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ATP Binding Cassette Subfamily A Member 4 (ABCA4) Gene (ASTRA)

Cancer and neoplasms

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Inavolisib Plus A Cdk4/6 Inhibitor And Letrozole Versus Placebo Plus A Cdk4/6 Inhibitor And Letrozole In Patients With Endocrine-Sensitive Pik3ca-Mutated, Hormone Receptor-Positive, Her2-Negative Advanced Breast Cancer (INAVO123)

Defining responses to infection and antibiotic treatment using wearable devices

A phase I/IIa, double-blinded, randomised controlled trial to assess the safety, tolerability, and early signs of anti-tumour activity of ITOP1 – a prime/boost viral vector vaccine targeting tumour specific antigens in subjects with surgically resectable oesophageal adenocarcinoma (VISTA)